Novo Nordisk says real-world study finds Ozempic 2 mg vs Mounjaro lowers major CV risk by 6%
Novo Nordisk said a real-world study of 636,525 adults with type 2 diabetes found escalated-dose Ozempic 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events versus switching to Mounjaro doses up to 15 mg, with results presented at the EASD meeting in Milan.